Therapy shown to relieve extreme pain in mice. Now moving towards human trials. Human stem cells and “pain-killing neurons” have successfully relieved chronic pain in mice. The breakthrough method may be tested on human patients suffering untreatable pain within five years. Researchers at the University of Sydney have used human stem cells to make pain-killing
Identification of GPR108 as ‘lock’ for adeno-associated virus vector (AAV) is crucial to this emerging novel class of genetic medicine and may provide framework for developing more targeted gene therapies Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types–the most commonly
University of Pittsburgh School of Medicine researchers have created a biodegradable nerve guide—a polymer tube—filled with growth-promoting protein that can regenerate long sections of damaged nerves, without the need for transplanting stem cells or a donor nerve. Source UPMC So far, the technology has been tested in monkeys, and the results of those experiments appeared
Blocking a protein makes cells shrink instead, causing fewer problems Techniques to genetically modify patient immune cells have revolutionized the fight against hard-to-treat cancers. But they can come with dangerous side effects. Now, researchers have found one reason why. A particularly messy form of cell death sparks severe inflammation in patients receiving CAR-T cell immunotherapy for blood
Original story from the International Society for Stem Cell Research The ISSCR is updating its Guidelines for Stem Cell Research and Clinical Translation to respond to recent scientific advances that include the use of pluripotent stem cell (PSC) to create models of early human embryo development. As the science continues to advance, it raises important
Researchers investigating childhood leukaemia have discovered that increasing MLL gene expression in iPSCs drives hematopoietic stem cell production, so could be the target of new therapies. Researchers have identified that increasing the expression of the normal form of the MLL gene can drive production of hematopoietic stem cells (HSCs). This not only provides a protocol
Source World Economic Forum The current market for stem cell therapies is growing at 36% per year and will rapidly expand when a breakthrough treatment for non-communicable disease or a lifestyle factor occurs. Funding is flowing into the sector from venture capitalists and large companies. With greater resources and an increasingly experienced talent pool, scientists
The UK and the NHS are providing the right environment and infrastructure to allow innovative cell and gene therapies to reach patients. International companies recognise the appeal of the UK cell and gene therapy ecosystem and are sponsoring the majority of the UK commercial clinical trials which account for 77% of the total 127 ongoing trials.
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center established at University Hospital of Heidelberg to provide ZYNTEGLO to patients bluebird bio, Inc. announced the launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a
ARM today announced the release of a report, “A Transformative Therapy Value Model for Rare Blood Diseases.” The report uses a refined value model to assess the impact of durable and potentially curative cell and gene therapies on health system costs. Produced in collaboration with the Marwood Institute, this report calculates the potential cost savings that
